In the present study, for the first time, we have demonstrated that the AR inhibitor, fidarestat, increases the sensitivity of CRC to DOX and decreases the cardiomyopathy associated with DOX in vitro and in vivo. The gene discussed is AR; the disease is cardiomyopathy.